Medicine

Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug. They made the advance in the field of so-called photopharmacology, a discipline that develops active substances which can be specifically activated or deactivated with the help of light. The study is being published today in the journal Nature Communications.

Researchers at EPFL have found that infection with a common bacterium that is linked to periodontal disease, oral cancers, and bad breath may cause a small increase in the risk of cardiovascular disease.

Up to now, the use of models to research the barrier that separates the circulatory from the nervous system has proven to be either limited or extremely complicated. Researchers at ETH Zurich have developed a more realistic model that can also be used to better explore new treatments for brain tumours.

The LOOP Zurich research centre is creating a central platform for the exchange of health data between the University of Zurich, ETH Zurich and the four university hospitals. This will allow data to be utilised quickly and easily to the benefit of patients. 

By combining a checkpoint inhibitor with a new immunocytokine, scientists at EPFL, Ludwig Institute for Cancer Research, CHUV and Roche have made a breakthrough in fighting against immunotherapy-resistant cancers.